| 1 | How do we make a fast and correct diagnosis of GIST and the specific subtype? | Define minimal standards for diagnosis | Who is eligible: a confirmed diagnosis of GIST and its subtype |
| 2 | What clinically useful information can and should be taken from a tumor, a biopsy, plasma or other sources to best prognosticate a patient or predict treatment? | Define standards for biobanking, decentralized and centralized testing including digital data storage | What each patient provides at entry: tissue, plasma and data |
| 3 | What are therapeutic vulnerabilities beyond the truncal event (KIT/PDGFRA)? | Come up with window of opportunity format to study those vulnerabilities | Who can enter a short window-of-opportunity cohort before surgery |
| 4 | How do we most efficiently and selectively inhibit the KIT and PDGFRA oncogenic signal? | Correlative project to study the target inhibition from surgical specimen | How surgical specimens are handled to measure target inhibition |
| 5 | Who should receive a medical treatment following or preceding surgery of a localized GIST? | Define a risk prognostication tool with the highest possible accuracy in order to reduce both over and undertreatment. | Which patients with localized GIST qualify for treatment before or after surgery |
| 6 | Which treatment should patients with localized GIST who are at risk for metastases receive to cure GIST? | Define current state of the art for every GIST genotype | The standard treatment each genotype receives |
| 7 | When should patients with GIST receive staging or follow-up studies during or following treatment for localized and metastatic disease? | Define imaging (and maybe plasma-based) studies during treatment | The imaging (and plasma) schedule during treatment |
| 8 | How do we best characterize resistance in treatment refractory GIST? | Define diagnostic approaches and tests | Which tests at progression assign a patient to a cohort |
| 9 | How can we predict and outrun resistance before it appears? | Design a protocol that treats resistance before it arises | Entry rules for cohorts that treat resistance before it arises |
| 10 | What is the role of surgery to cure? | Define limits and prerequisites for surgery in metastatic disease | Who qualifies for surgery in metastatic disease |
| 11 | Why do some tumor cells survive treatment without being resistant, and how do we eliminate them? | Set up a translational program and define the type and number of samples needed to answer the goal | The type and number of samples each patient contributes |
| 12 | Which models do we need to develop and which should we prioritize on our road to the cure? | Add correlative studies that may help to develop those models | Optional samples for model development |
| 13 | Can and should radiotherapy be part of the armamentarium of treatments to CURE GIST? | If confirmed that protocol needs a section that defines the role and a standard in a metastatic setting | Who qualifies for radiotherapy in metastatic disease |
| 14 | How do we know, for each patient, how much treatment is needed? | Choose and validate the risk model used for cohort assignment (proposed) | Which risk model assigns patients to a treatment intensity |
| 15 | How do we run trials fast enough and appreciate the individual genotype of GIST? | Write the master protocol and the rules for adding and closing arms (proposed) | The master protocol: how arms are added, adapted and closed |
| 16 | What is the best treatment for GIST without KIT or PDGFRA mutations? | Define cohorts and standards for GIST without KIT or PDGFRA mutations (proposed) | Cohorts for GIST without KIT or PDGFRA mutations |